Publications by authors named "Jose Maria Auge"
Differential diagnosis of suspicious lung masses is essential for the selection of the appropriate therapy strategy. While non-small cell lung cancer (NSCLC) in early stages and single lung metastases from other cancers mostly are resected by surgery, late stage NSCLC, small cell lung cancers (SCLC) and multiple lung metastases are treated by systemic chemo- and/or radiotherapeutic approaches. In many patients, biopsies for the histopathological subtyping can not be taken due to multimorbidity and instable clinical conditions of the patient or unfavourable localisation of the tumor.
View Article and Find Full Text PDFTumor marker serum levels were prospectively studied in 289 patients with suspected, but unconfirmed, lung cancer and in 513 patients with lung cancer [417 non-small cell lung cancer (NSCLC) patients and 96 small cell lung cancer (SCLC) patients]. In patients with benign disease, abnormal serum levels were found for the following tumor markers: CEA (in 6.6% of patients); CA 19.
View Article and Find Full Text PDFBackground: Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer.
Methods: The analytical and clinical performance of the Access BR Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA15-3 on the Elecsys System (Roche Diagnostics).
Results: Total imprecision (% CV) of the BR Monitor ranged between 5.
Article Synopsis
- The Access GI Monitor assay is an effective tool for measuring CA19-9 levels, showing good reliability with low imprecision and strong reproducibility across multiple labs in Europe.
- The assay demonstrates a strong correlation with the reference method (Elecsys CA19-9), making it a viable option for monitoring pancreatic cancer and potentially other cancers.
- Findings indicate that the GI Monitor is particularly useful for differentiating pancreatic cancer from benign conditions, with a diagnostic accuracy (AUC) comparable to the reference assay.
Background: Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer.
Methods: The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA125 on the Elecsys System (Roche Diagnostics).
Results: Total imprecision (% CV) of the OV Monitor ranged between 3.
Objective: To evaluate serum vascular endothelial growth factor (VEGF) as a prognostic factor in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with metronomic (weekly) paclitaxel.
Design: Before-and-after trial.
Patients: A total of 33 consecutive patients were enrolled.